GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal
by Zacks Equity Research
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
GSK (GSK) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $31.02, moving -0.58% from the previous trading session.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
by Zacks Equity Research
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
by Kinjel Shah
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $31.51, marking a +0.06% move from the previous day.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
by Zacks Equity Research
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?
by Zacks Equity Research
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GSK's NDA for Daprodustat to be Reviewed by an FDA Panel
by Zacks Equity Research
GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.
Gilead (GILD) Announces Positive New Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $31.85 in the latest trading session, marking a +0.5% move from the prior day.
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
by Zacks Equity Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
by Zacks Equity Research
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
by Zacks Equity Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
by Zacks Equity Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
by Zacks Equity Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
by Zacks Equity Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
by Zacks Equity Research
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped
by Zacks Equity Research
Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.